namely UCB's Keppra (levetiracetam) and Briviact (brivaracetam), bind to SV2A and inhibit its activity as a way to treat epilepsy. Syndesi's approach is to modulate the activity of SV2A in other ...

It possesses a selective binding affinity for SV2A, 13 times higher than that of levetiracetam, and also shows an ability to inhibit sodium channels. [23] Brivaracetam has nearly complete ...

Levetiracetam 100mg/mL; IV infusion after dilution. Infuse over 15mins. Partial onset: ≥16yrs: initially 500mg twice daily; may increase at 2-week intervals in increments of 1g/day; max 3g/day ...

Levetiracetam 500mg, 750mg; ext-rel tabs. Swallow whole. ≥12yrs (≥50kg): initially 1g once daily; may increase at 2-week intervals in increments of 1g/day; max 3g/day. Renal impairment: CrCl ...